

Claim Amendments

Please amend the claims as shown below.

1. (currently amended) A crystalline solid famciclovir form I, characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ , wherein the crystalline solid famciclovir contains less than about 5% wt of another famciclovir crystalline form.
2. (original) The crystalline solid famciclovir of claim 1, further characterized by a XRD pattern with peaks at 8.2, 10.4, 14.5, 17.0, 17.7, 19.5, 20.6, 21.1, 22.3, 23.0, 23.9, 24.4, 25.6, 26.5, 28.6, 29.0 and 32.6 ± 0.2 deg. 2θ .
3. (original) The crystalline solid famciclovir of claim 2, further characterized by a XRD pattern as substantially depicted in Fig. 1.
4. (canceled)
5. (currently amended) The crystalline solid famciclovir of any one of claims 1-3, wherein the crystalline solid famciclovir contains less than about 5% wt of form II.
6. (currently amended) The crystalline solid famciclovir of claim 5 ~~[[[4]]]~~, wherein the crystalline solid famciclovir contains less than about 1% wt of ~~other~~ another famciclovir crystalline form ~~forms~~.
7. (original) The crystalline solid famciclovir of claim 6, wherein the crystalline solid famciclovir contains less than about 1% wt of form II.
8. (currently amended) A crystalline solid famciclovir form II, characterized by a XRD pattern with peaks at 16.2 and 16.4 ± 0.2 deg. 2θ , wherein the crystalline solid famciclovir contains less than about 5% wt of another famciclovir crystalline form.
9. (original) The crystalline solid famciclovir of claim 8, further characterized by a XRD pattern with peaks at 8.3, 14.6, 17.8, 19.7, 20.7, 21.2, 24.5 and 25.6 ± 0.2 deg. 2θ .
10. (original) The crystalline solid famciclovir of claim 9, further characterized by a XRD pattern as substantially depicted in Fig. 2.
11. (currently amended) A crystalline solid famciclovir solvate ~~form III~~, characterized by a XRD pattern with peaks at 6.6 and 13.0 ± 0.2 deg. 2θ .
12. (currently amended) The crystalline solid famciclovir solvate of claim 11, further characterized by a XRD pattern with peaks at 15.9, 16.7, 18.4, 19.6, 24.5, 25.0 and 26.2 ± 0.2 deg. 2θ .

13. (currently amended) The crystalline solid famciclovir solvate of claim 12, further characterized by a XRD pattern as substantially depicted in Fig. 3.
14. (currently amended) The crystalline solid famciclovir solvate of claim 11, wherein the crystalline solid ~~of~~ famciclovir solvate is a methanol solvate.
15. (currently amended) The crystalline solid famciclovir solvate of claim 11, wherein the crystalline solid ~~of~~ famciclovir solvate is an ethanol solvate.
16. (original) Crystalline solid famciclovir methanol solvate.
17. (original) Crystalline solid famciclovir ethanol solvate.
18. (original) A process for preparing the crystalline solid famciclovir of claim 1, comprising the steps of:
 - a) triturating an anhydrous famciclovir form in an organic solvent selected from the group consisting of isopropyl alcohol, acetonitrile, and diethylether; and
 - b) isolating the crystalline solid famciclovir of claim 1.
19. (original) A crystalline solid famciclovir form I prepared by triturating an anhydrous famciclovir form in an organic solvent selected from the group consisting of isopropyl alcohol, acetonitrile, and diethylether.
20. (original) A process for preparing the crystalline solid famciclovir of claim 1, comprising the steps of:
 - a) heating crystalline solid famciclovir of claim 11 to about 40⁰C to about 90⁰C; and
 - b) isolating the crystalline solid famciclovir of claim 1.
21. (original) The process of claim 20, wherein the heating of the crystalline solid famciclovir of claim 11 is performed at a temperature of about 60⁰C to about 70⁰C.
22. (original) A process for preparing the crystalline solid famciclovir of claim 1, comprising the steps of:
 - a) heating famciclovir monohydrate to about 40⁰C to about 80⁰C; and
 - b) isolating the crystalline solid famciclovir of form I.
23. (currently amended) The process of claim 22, wherein step a) is performed by heating a mixture of the famciclovir monohydrate and includes the crystalline solid famciclovir form I characterized by a XRD pattern with peaks at 15.5 and 15.9 ± 0.2 deg. 2θ of claim 1.

24. (original) The process of claim 22, wherein the heating of famciclovir monohydrate is performed at a temperature of about 60⁰C to about 70⁰C.
25. (currently amended) A process for preparing the crystalline solid famciclovir of claim 1, comprising the steps of:
 - a) heating the crystalline solid famciclovir form II, characterized by a XRD pattern with peaks at 16.2 and 16.4 ± 0.2 deg. 2θ, of claim 8 to about 40⁰C to about 90⁰C; and
 - b) isolating the crystalline solid famciclovir of claim 1.
26. (currently amended) The processes of any one of claims 18, 20, 22 and 25, wherein the isolated crystalline solid famciclovir ~~of claim 1~~ contain less than about 5% wt of other famciclovir crystalline forms.
27. (currently amended) The processes of any one of claims 18, 20, 22 and 25, wherein the isolated crystalline solid famciclovir ~~of claim 1~~ contains less than about 5% wt of crystalline famciclovir form II the form of claim 8.
28. (currently amended) The process of claim 26, wherein the isolated crystalline solid famciclovir ~~of claim 1~~ contain less than about 1% wt of other famciclovir crystalline forms.
29. (currently amended) The process of claim 28, wherein the isolated crystalline solid famciclovir ~~of claim 1~~ contains less than about 1% wt of crystalline famciclovir form II the form of claim 8.
30. (currently amended) A process for preparing the crystalline solid famciclovir of claim 1, comprising the steps of:
 - a) providing a solution of famciclovir in an organic solvent selected from the group consisting of dichloromethane, chloroform, acetonitrile, ethylacetate, acetone, THF, diethyl ether/dichloromethane mixture, dichloromethane/toluene mixture, ethylacetate/toluene mixture, acetonitrile/toluene mixture[[[,]]] and dimethylacetamide ~~and isopropylalcohol~~,
 - b) cooling the solution, and
 - c) isolating the crystalline solid famciclovir of claim 1.
31. (currently amended) A process for preparing the crystalline solid famciclovir of claim 8, comprising the steps of:

- a) providing a solution of famciclovir in ~~an organic solvent selected from the group consisting of ethanol and n-butanol,~~
 - b) cooling the solution whereby the crystalline solid famciclovir form II crystallizes, and
 - c) isolating the crystalline solid famciclovir of claim 8.
32. (currently amended) A process for preparing a mixture of crystalline solid famciclovir form II, characterized by a XRD pattern with peaks at 16.2 and 16.4 ± 0.2 deg. 2θ, of ~~claim 8~~ and crystalline solid famciclovir of claim 1, comprising the steps of:
- a) providing a solution of famciclovir in an organic solvent selected from the group consisting of chloroform, ethylacetate, diethyl ether/dichloromethane mixture, tetrahydrofuran, acetonitrile/toluene mixture, dimethylacetamide and isopropanol,
 - b) cooling the solution, and
 - c) isolating the mixture of the crystalline solid famciclovir form II, characterized by a XRD pattern with peaks at 16.2 and 16.4 ± 0.2 deg. 2θ, of ~~claim 8~~ and the crystalline solid famciclovir of claim 1.
33. (original) A process for preparing the crystalline solid famciclovir of claim 11, comprising the steps of:
- a) triturating an anhydrous famciclovir in methanol; and
 - b) isolating the crystalline solid famciclovir of claim 11.
34. (original) A process of preparing a mixture of the crystalline solid famciclovir of claim 11 and the crystalline solid famciclovir of claim 1, comprising the steps of:
- a) triturating an anhydrous famciclovir in ethanol; and
 - b) isolating the mixture of the crystalline solid famciclovir of claim 11 and the crystalline solid famciclovir of claim 1.
35. (currently amended) A process of preparing a crystalline solid famciclovir monohydrate ~~monhydrate~~, comprising the steps of:
- a) providing a solution of famciclovir in an organic solvent selected from the group consisting of acetonitrile, ethyl acetate, acetone, isopropyl alcohol, tetrahydrofuran, ethanol/water mixture, ~~acetone/water mixture~~, DMF/water mixture, DMA/water mixture, acetonitrile/water mixture, methanol/water mixture, tetrahydrofuran/water mixture, and isopropyl alcohol/water mixture; and
 - b) cooling the solution; and

- c) isolating the crystalline solid famciclovir monohydrate.
36. (currently amended) A process for preparing a mixture of the crystalline solid famciclovir solvate of claim 11 and crystalline solid famciclovir monohydrate, comprising the steps of:
- a) triturating anhydrous famciclovir in an organic solvent selected from the group consisting of isopropyl alcohol and ethanol; and
 - b) isolating the mixture of the crystalline solid famciclovir solvate of claim 11 and crystalline solid famciclovir monohydrate.

37. (currently amended) A solid pharmaceutical composition comprising the crystalline solid famciclovir of claim 1 and a pharmaceutically-acceptable excipient, ~~wherein the crystalline solid famciclovir of claim 1 contains less than about 5% wt of other famciclovir crystalline forms.~~
38. (currently amended) The solid pharmaceutical composition of claim 37, wherein the crystalline solid famciclovir of claim 1 contains less than about 1% wt of ~~other~~ another famciclovir crystalline form ~~forms~~.
39. (currently amended) A solid pharmaceutical composition comprising the crystalline solid famciclovir of claim 8 and a pharmaceutically-acceptable excipient, ~~wherein the crystalline solid famciclovir form II contains less than about 5% wt of other famciclovir crystalline forms.~~
40. (currently amended) The solid pharmaceutical composition of claim 39, wherein the crystalline solid famciclovir of claim 8 contains less than about 1% wt of ~~other~~ another famciclovir crystalline form ~~forms~~.
41. (currently amended) A solid pharmaceutical composition comprising a crystalline solid famciclovir solvate of claim 11 and a pharmaceutically-acceptable excipient, wherein the crystalline solid famciclovir solvate of claim 11 ~~form III~~ contains less than about 5% wt of another ~~other~~ famciclovir crystalline form ~~forms~~.
42. (currently amended) The solid pharmaceutical composition of claim 41, wherein the crystalline solid famciclovir of claim 11 contains less than about 1% wt of another ~~other~~ famciclovir crystalline form ~~forms~~.
43. (currently amended) A method of treating a human in need of treatment with famciclovir comprising administering to the human the pharmaceutical composition of any one of claims 37-42.